Sign in

    Shelby Hill

    Research Analyst at RBC Capital Markets

    Shelby Hill is an equity research analyst at RBC Capital Markets, specializing in coverage of the biotechnology sector with a particular focus on companies such as Ultragenyx Pharmaceutical Inc. Hill's research contributions have included participation in earnings calls and providing company-specific analysis, reflecting specialized insight within the life sciences industry. While publicly available records indicate activity dating to at least 2025 and research engagement at RBC, further details on career timeline, historical performance metrics, and professional credentials have not been widely published. Hill’s ongoing coverage contributes to market understanding for targeted biopharma clients.

    Shelby Hill's questions to Ultragenyx Pharmaceutical (RARE) leadership

    Shelby Hill's questions to Ultragenyx Pharmaceutical (RARE) leadership • Q2 2025

    Question

    On behalf of Luca Eci from RBC Capital Markets, Shelby Hill asked for more color on the Sanfilippo CRL, referencing prior comments about shipping validation and a stringent inspector, and questioned if the FDA was 'missing the forest for the trees.'

    Answer

    Emil Kakkis, Founder, President & CEO, responded that it is the FDA's job to scrutinize details ('check every tree') and that CMC rigor is essential. He emphasized that the company's focus is on methodically addressing all the issues raised in the CRL, which they believe are entirely manageable, rather than dwelling on the inspection process.

    Ask Fintool Equity Research AI